Skip to content
Triangle logo TriangleGet started
← Uterine Sarcoma

NCT01367301 · STUDY IN CONTEXT

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

One-year recurrence-free survival probability will be estimated, with 95% confidence limits based on exact methods for the binomial distribution.

Recurrence-free survival data was not collected/aggregated and therefore not analyzed.

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-uterine-sarcoma
nct id
NCT01367301
trial label
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer
applicability
narrower
applicability note
Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
1
harms Count
1
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-uterine-sarcoma
    nct id
    NCT01367301
    outcome key
    om-0000
    source section id
    NCT01367301-om-0000
    source outcome index
    0
    endpoint
    Recurrence-free Survival
    endpoint definition
    One-year recurrence-free survival probability will be estimated, with 95% confidence limits based on exact methods for the binomial distribution.
    time origin
    Date of entry to date of reappearance of disease, assessed at 1 year
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Recurrence-free survival data was not collected/aggregated and therefore not analyzed.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-uterine-sarcoma
    nct id
    NCT01367301
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Treatment (Paclitaxel, Carboplatin, Radiotherapy)
    regimen
    CHEMOTHERAPY (weeks 1-9, 14-22): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses during weeks 1-9 and 14-22. RADIATION THERAPY (weeks 8-16): Patients undergo external beam pelvic radiation therapy once a day, 5 days a week for 5 weeks during weeks 8-13. Patients then undergo HDR brachytherapy or IMRT once weekly during weeks 14-16. paclitaxel: Given IV carboplatin: Given IV external beam radiation therapy: Undergo external beam radiation therapy brachytherapy: Undergo HDR brachytherapy intensity-modulated radiation therapy: Undergo IMRT laboratory biomarker analysis: Correlative studies
    analyzed count
    0
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01367301-om-0000#groups/OG000
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-uterine-sarcoma
    nct id
    NCT01367301
    harm key
    EG000
    source section id
    NCT01367301-ae
    event group key
    EG000
    event group label
    Treatment (Paclitaxel, Carboplatin, Radiotherapy)
    serious affected
    0
    serious at risk
    11
    other affected
    2
    other at risk
    11
    frequency threshold
    0
    collection period
    Every 3 months for the first 2 years and every 6 months for the next 3 years. Up to 5 years total as described in Section 7.4 of the Study Protocol.
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice